Catalog5 refs
Survodutide
Metabolicglp1Weight LossResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Circulation
Overview
An injectable dual agonist that hits both the GLP-1 and glucagon receptors, developed by Boehringer Ingelheim and Zealand Pharma. It is being tested for obesity and for fatty liver disease (MASH), and it carries an FDA Breakthrough Therapy designation for MASH. The GLP-1 receptor arm dampens appetite, slows stomach emptying, and improves blood sugar handling, while the glucagon receptor arm raises energy expenditure and pushes the liver to burn fat rather than store it.
Primary Uses
Obesity treatment
Metabolic dysfunction-associated steatohepatitis (MASH/NASH) treatment
Weight loss
Hepatic lipid oxidation
Liver fibrosis improvement
Obesity/NAFLD research
GLP-1/glucagon dual agonism
Liver-fat reduction studies
Weight-management trials
Obesity Without Diabetes
Obesity With Type 2 Diabetes
Sustained Weight Management
MASH Treatment
Liver Fat Reduction
Type 2 Diabetes Control
obesity
type 2 diabetes
blood glucose reduction
increased energy expenditure
MASH (fatty liver disease)
Protocol Reference
Dose
Titrated up to 4.8mg weekly
Frequency
weekly
Half-life
Long-acting; supports once-weekly dosing
Route
Subcutaneous injection
Evidence
Phase 3 Clinical Trials - FDA Breakthrough Therapy Designation for MASH / Phase 2 trials / Extensively Studied / Clinical trials ongoing (disputed)
Research References· 2
Research Models
Human
Also in Metabolic